We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Johnson & Johnson (JNJ) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
Read MoreHide Full Article
Analysts on Wall Street project that Johnson & Johnson (JNJ - Free Report) will announce quarterly earnings of $2.85 per share in its forthcoming report, representing an increase of 2.9% year over year. Revenues are projected to reach $25.14 billion, increasing 5.9% from the same quarter last year.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 0.2% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
Given this perspective, it's time to examine the average forecasts of specific Johnson & Johnson metrics that are routinely monitored and predicted by Wall Street analysts.
Analysts expect 'Sales- Innovative Medicine- WW' to come in at $16.16 billion. The estimate points to a change of +6.3% from the year-ago quarter.
According to the collective judgment of analysts, 'Sales- MedTech- Total' should come in at $8.96 billion. The estimate points to a change of +4.9% from the year-ago quarter.
The average prediction of analysts places 'Sales- MedTech- Cardiovascular- WW' at $2.53 billion. The estimate suggests a change of +9.3% year over year.
Analysts forecast 'Sales- Innovative Medicine- Oncology- DARZALEX- WW' to reach $4.16 billion. The estimate indicates a change of +17.5% from the prior-year quarter.
Analysts predict that the 'Sales- Innovative Medicine- Oncology- CARVYKTI- WW' will reach $640.24 million. The estimate indicates a year-over-year change of +45.8%.
The combined assessment of analysts suggests that 'Sales- Innovative Medicine- Neuroscience- SPRAVATO- WW' will likely reach $575.14 million. The estimate indicates a change of +38.9% from the prior-year quarter.
Analysts' assessment points toward 'Sales- MedTech- Cardiovascular- Other Cardiovascular- WW' reaching $98.02 million. The estimate indicates a change of -5.8% from the prior-year quarter.
Based on the collective assessment of analysts, 'Sales- MedTech- Cardiovascular- ABIOMED- WW' should arrive at $505.37 million. The estimate indicates a change of +12.8% from the prior-year quarter.
The consensus among analysts is that 'Sales- International' will reach $10.75 billion. The estimate indicates a change of +5.5% from the prior-year quarter.
The consensus estimate for 'Sales- MedTech- Cardiovascular- Electrophysiology- WW' stands at $1.58 billion. The estimate suggests a change of +7.3% year over year.
It is projected by analysts that the 'Sales- Innovative Medicine- Oncology- DARZALEX- US' will reach $2.43 billion. The estimate indicates a year-over-year change of +20.5%.
The collective assessment of analysts points to an estimated 'Organic Sales Growth (Operational growth)' of 6.3%. The estimate is in contrast to the year-ago figure of 4.6%.
Shares of Johnson & Johnson have experienced a change of +8.7% in the past month compared to the +2.2% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), JNJ is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Johnson & Johnson (JNJ) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
Analysts on Wall Street project that Johnson & Johnson (JNJ - Free Report) will announce quarterly earnings of $2.85 per share in its forthcoming report, representing an increase of 2.9% year over year. Revenues are projected to reach $25.14 billion, increasing 5.9% from the same quarter last year.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 0.2% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
Given this perspective, it's time to examine the average forecasts of specific Johnson & Johnson metrics that are routinely monitored and predicted by Wall Street analysts.
Analysts expect 'Sales- Innovative Medicine- WW' to come in at $16.16 billion. The estimate points to a change of +6.3% from the year-ago quarter.
According to the collective judgment of analysts, 'Sales- MedTech- Total' should come in at $8.96 billion. The estimate points to a change of +4.9% from the year-ago quarter.
The average prediction of analysts places 'Sales- MedTech- Cardiovascular- WW' at $2.53 billion. The estimate suggests a change of +9.3% year over year.
Analysts forecast 'Sales- Innovative Medicine- Oncology- DARZALEX- WW' to reach $4.16 billion. The estimate indicates a change of +17.5% from the prior-year quarter.
Analysts predict that the 'Sales- Innovative Medicine- Oncology- CARVYKTI- WW' will reach $640.24 million. The estimate indicates a year-over-year change of +45.8%.
The combined assessment of analysts suggests that 'Sales- Innovative Medicine- Neuroscience- SPRAVATO- WW' will likely reach $575.14 million. The estimate indicates a change of +38.9% from the prior-year quarter.
Analysts' assessment points toward 'Sales- MedTech- Cardiovascular- Other Cardiovascular- WW' reaching $98.02 million. The estimate indicates a change of -5.8% from the prior-year quarter.
Based on the collective assessment of analysts, 'Sales- MedTech- Cardiovascular- ABIOMED- WW' should arrive at $505.37 million. The estimate indicates a change of +12.8% from the prior-year quarter.
The consensus among analysts is that 'Sales- International' will reach $10.75 billion. The estimate indicates a change of +5.5% from the prior-year quarter.
The consensus estimate for 'Sales- MedTech- Cardiovascular- Electrophysiology- WW' stands at $1.58 billion. The estimate suggests a change of +7.3% year over year.
It is projected by analysts that the 'Sales- Innovative Medicine- Oncology- DARZALEX- US' will reach $2.43 billion. The estimate indicates a year-over-year change of +20.5%.
The collective assessment of analysts points to an estimated 'Organic Sales Growth (Operational growth)' of 6.3%. The estimate is in contrast to the year-ago figure of 4.6%.
View all Key Company Metrics for Johnson & Johnson here>>>Shares of Johnson & Johnson have experienced a change of +8.7% in the past month compared to the +2.2% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), JNJ is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .